Skip to Main Content

Lawrence H. Fong


Genitourinary oncologist
Cancer immunotherapist and laboratory head

Dr. Lawrence Fong is a medical oncologist who specializes in immunotherapy to care for cancer patients with an emphasis on genitourinary cancers (those involving the genital or urinary organs).

A physician-scientist, Fong studies new immunotherapies for cancer. He is nationally known for his work on cancer vaccines and immune checkpoint inhibitors (drugs that prevent an immune system response that can stop cancer cells from being destroyed). He has helped conduct numerous clinical trials (evaluations of potential new treatments using human volunteers) and is the principal investigator on multiple research projects that have received grants from federal agencies and private foundations. As the leader of UCSF's cancer immunotherapy program, he helps to develop new treatments through early-phase clinical trials of novel immunotherapies. His laboratory focuses on understanding why current treatments work in some patients but not others.

Fong earned his medical degree at Stanford University. He completed a residency in internal medicine at the University of Washington. He completed an oncology fellowship at Stanford Medicine.

Fong joined the UCSF faculty in 2001 and is the Efim Guzik Distinguished Professor in Cancer Biology. He has published more than 100 peer-reviewed scientific articles and multiple book chapters. He has lectured nationally and internationally on cancer immunotherapy.

  • Education

    Stanford University School of Medicine, MD, 1992

  • Residencies

    University of Washington, Internal Medicine, 1994

  • Fellowships

    Stanford Medicine, Oncology, 1997

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title


My goal is to improve treatment of cancer through immunotherapy.

Where I see patients (4)

    My reviews


    Overall Experience
    116 Ratings
    About our process
    Jul 08, 2023
    Dr. Fong was fabulous.
    Jun 03, 2023
    Dr. Fong is an excellent care provider in all aspects.
    Mar 18, 2023
    Mar 03, 2023
    Dr. Fong has always treated me with great respect as a patient and human being and I therefore trust him with my life.
    Feb 09, 2023
    Responsive & Caring & Knowledgeable.
    Jan 29, 2023
    Dr. Fong listened to me and my wife's questions asked for clarifications and responded directly the questions.
    Jan 26, 2023
    Dr. Fong is an excellent practitioner. Awesome bedside manners as well.
    Nov 25, 2022
    Dr. Fong is a great communicator he uses language with precision so his explanations are very clear and concise.
    Oct 27, 2022
    Dr. Fong is the gold standard of professionalism.Never met another physician who even comes close.
    Oct 22, 2022
    Dr. Fong is attentive and is a great communicator.
    Jul 28, 2022
    Dr. Fong is an exceptionally talented physician an gifted and inspiring leader with impeccable character. I feel honored to have him as my personal guide on my journey with UCSF.
    Jul 14, 2022
    Dr. Fong answered all my questions clear and concise. A caring physician.
    Jul 14, 2022
    Dr. Fong is one of my very favorite doctors. He u it s a calm quiet humble man who shows concern for my issues and us ready to offer explanations. Just the best!
    Apr 16, 2022
    Dr. Fong is consistently thorough responsive and caring.
    Feb 03, 2022
    Dr Fong listens well and provided ideas for possible therapies to treat my case ( prostate cancer)
    Nov 11, 2021
    Dr. Fong communicates well and has a warm and friendly manner
    Decorative Caduceus

    Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition

    ORR by RECIST version 1.1


    Decorative Caduceus

    A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma


    Decorative Caduceus

    An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination ...


    Decorative Caduceus

    Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior ...

    A positive response is defined as a ≥40% increase in the number of infiltrating cluster of differentiation 3 (CD3) + T cells between the pre-treatment biopsy at baseline and the post-treatment RP specimen. Thus, a negative respons...